Jonae R. Barnes
Investor Relations Contact bei ATEA PHARMACEUTICALS, INC.
Profil
Jonae R.
Barnes is currently the SVP-Investor Relations & Corporate Communications at Atea Pharmaceuticals, Inc. She previously worked as the SVP-Investor Relations & Corporate Communications at Sumitomo Pharma America, Inc. from 2007 to 2009.
She also held positions as VP-Investor Relations & Corporate Communications at Agenus, Inc., Head-Investor Relations at Idenix Pharmaceuticals LLC, and Senior VP-Investor Relations & Public Relations at Poxel SA. Barnes received a graduate degree from Boston University and an undergraduate degree from Suffolk University.
Aktive Positionen von Jonae R. Barnes
| Unternehmen | Position | Beginn |
|---|---|---|
| ATEA PHARMACEUTICALS, INC. | Investor Relations Contact | 19.01.2021 |
Ehemalige bekannte Positionen von Jonae R. Barnes
| Unternehmen | Position | Ende |
|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Investor Relations Contact | 01.12.2009 |
| POXEL | Investor Relations Contact | - |
| AGENUS INC. | Investor Relations Contact | - |
| IDENIX PHARMACEUTICALS INC | Investor Relations Contact | - |
Ausbildung von Jonae R. Barnes
| Boston University | Graduate Degree |
| Suffolk University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| POXEL | Health Technology |
| ATEA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
